News
-
GlaxoSmithKline and Theravance have announced the beginning of the FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI in patients with… Read more . . .
-
DPI developer Respira Therapeutics has hired inhalation drug development pioneer Andy Clark as Vice President and Chief Technology Officer. Clark most recently served as Site Head and CTO at the Novartis pulmonary development facility in… Read more . . .
-
Lightlake Therapeutics has announced today that it has hired former Mundipharma Head of Medical Affairs for New Products Arvind Agrawal as Executive VP, Medical Affairs, effective January 2015. Agrawal has also held Medical Affairs positions… Read more . . .
-
Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT) has announced that it received Orphan Drug Designation from the FDA last fall for its AIT-CF high dose nitric oxide formulation for the treatment of lung infections in… Read more . . .
-
Innovus Pharmaceuticals has announced that the acquisition of Novalere FP and its FlutiCare fluticasone propionate nasal spray. According to documents related to the merger filed with the US Securities and Exchange Commission (SEC), Novalere FP… Read more . . .
-
AstraZeneca will pay Actavis $600 million plus royalties for US and Canadian rights to Daliresp roflumilast and the Tudorza Pressair aclidinium bromide DPI, plus development rights to an aclidinium/formoterol DPI which was approved in Europe… Read more . . .
-
Oxford Lasers has announced the launch of its EnVision QC system for spray pattern and plume geometry testing of both MDIs and nasal sprays for quality control purposes. The Envision QC system includes automatic device… Read more . . .
-
Consort Medical has announced that its Bespak subsidiary has entered into a multi-year agreement to supply its proprietary integrated dose counter system and the valve for a commercial pMDI. This is the first commercial use… Read more . . .
-
Novartis Pharmaceuticals Canada has announced the launch of the Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI for the treatment of COPD in Quebec, the first province in Canada to reimburse the inhaler. The Régie de l’assurance maladie… Read more . . .
-
Mast Therapeutics has announced that the first patients have been dosed in two Phase 2a studies of AIR001 sodium nitrite inhalation solution for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.